AC5 Topical Hemostat

About Arch Therapeutics

Arch Therapeutics' mission is to improve surgical and wound care outcomes through its innovative self-assembling peptide technology, which forms a protective barrier at the wound site. The company's key achievement is the U.S. commercial launch of its AC5 Advanced Wound System for exuding wounds. Its current strategy is focused on driving adoption and sales of AC5 while leveraging its core platform for potential future applications in hemostasis. As a publicly traded entity, Arch operates in the competitive but high-value medical device sector for bleeding control.

Therapeutic Areas